Cullinan Therapeutics
CGEM
14.90
-0.73
-4.67%
Cullinan Therapeutics
US · CGEM
#3243 by market cap
Listed 2021
14.90
-0.73
-4.67%
Live - 5344 symbols - heartbeat 253s ago
· 2026-10-08 10:00
Pre-market
15.60
-0.19%
After-hours
15.63
0.00%
- Market cap
- 958.88M
- P/E (TTM)i
- -4.79
- P/Bi
- 2.98
- EPSi
- -3.36
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on CGEM?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 18.94M | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.00M | 5.48M | 17.12M | 29.15M | 40.19M | 42.49M | 54.02M | 54.25M |
| Research & development | 9.58M | 16.79M | 43.21M | 57.75M | 91.95M | 148.16M | 142.90M | 187.40M |
| Operating profit | -14.59M | -22.27M | -60.34M | -67.95M | -132.14M | -190.65M | -196.92M | -241.65M |
| Pretax profit | -14.19M | -21.65M | -59.46M | -67.49M | 151.32M | -169.22M | -167.46M | -219.88M |
| Tax | -- | -- | -- | 0 | 42.12M | -14.12M | 117.00K | 0 |
| Net profit | -14.19M | -21.65M | -59.46M | -67.49M | 109.20M | -155.10M | -167.58M | -219.88M |
| Basic EPS | -1 | -1 | -1 | -2 | 2 | -3 | -3 | -3 |
| Diluted EPS | -1.24 | -1.07 | -1.37 | -1.52 | 2.38 | -3.21 | -2.78 | -3.36 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.54M | 14.77M | 13.63M | 12.31M | 11.57M | 12.82M |
| Research & development | 41.46M | 61.03M | 41.97M | 42.95M | 42.12M | 44.44M |
| Operating profit | -55.00M | -75.80M | -55.60M | -55.26M | -53.70M | -57.25M |
| Pretax profit | -48.50M | -70.06M | -50.61M | -50.71M | -49.66M | -53.70M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -48.50M | -70.06M | -50.61M | -50.71M | -49.66M | -53.70M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.74 | -1.07 | -0.77 | -0.77 | -0.75 | -0.81 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 34.22M | 100.09M | 212.28M | 296.56M | 474.47M | 480.19M | 414.67M | 386.76M |
| Cash & ST investments | 33.83M | 98.63M | 210.21M | 290.47M | 467.29M | 467.07M | 398.98M | 377.90M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 34.64M | 100.46M | 214.71M | 437.19M | 561.12M | 484.18M | 621.82M | 448.37M |
| Total current liabilities | 1.32M | 2.52M | 14.32M | 11.75M | 22.50M | 28.14M | 30.65M | 37.74M |
| Short-term debt | -- | -- | -- | -- | 1.60M | 1.44M | 1.30M | 780.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 55,290,000.00 | 140,370,000.00 | 14,394,000.00 | 11,811,000.00 | 26,088,000.00 | 30,287,000.00 | 31,496,000.00 | 39,644,000.00 |
| Total equity | -20.65M | -39.91M | 200.31M | 425.37M | 535.03M | 453.90M | 590.33M | 408.73M |
| Retained earnings | -20.87M | -41.54M | -93.34M | -158.91M | -47.70M | -200.86M | -368.24M | -588.12M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 317.77M | 275.91M | 342.24M | 386.76M | 361.41M | 341.97M |
| Cash & ST investments | 303.83M | 265.48M | 332.60M | 377.90M | 351.89M | 334.54M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 579.68M | 520.33M | 484.13M | 448.37M | 402.98M | 363.79M |
| Total current liabilities | 27.35M | 28.06M | 32.76M | 37.74M | 35.15M | 40.63M |
| Short-term debt | 1.35M | 1.39M | 1.19M | 780.00K | 725.00K | 666.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 27,842,000.00 | 28,183,000.00 | 32,757,000.00 | 39,644,000.00 | 36,812,000.00 | 42,033,000.00 |
| Total equity | 551.84M | 492.15M | 451.37M | 408.73M | 366.17M | 321.75M |
| Retained earnings | -416.74M | -486.80M | -537.41M | -588.12M | -637.78M | -691.48M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.55M | -20.90M | -29.77M | -43.43M | -126.66M | -134.28M | -145.30M | -175.75M |
| Depreciation & amortization | 43.00K | 70.00K | 62.00K | 53.00K | 93.00K | 310.00K | 306.00K | 311.00K |
| Free cash flow | -13.81M | -20.92M | -29.78M | -43.43M | -127.80M | -134.48M | -145.30M | -175.80M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.00K | -- | 145.45M | 267.27M | 0 | 38.39M | 262.65M | 0 |
| Ending cash balance | 33.83M | 63.25M | 168.20M | 59.77M | 156.15M | 98.43M | 83.01M | 88.33M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -43.16M | -57.61M | -36.88M | -38.11M | -46.05M | -38.22M |
| Depreciation & amortization | 76.00K | 77.00K | 79.00K | 79.00K | 79.00K | 79.00K |
| Free cash flow | -43.16M | -57.61M | -36.92M | -38.12M | -46.05M | -38.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 76.66M | 72.82M | 103.34M | 88.33M | 75.08M | 78.64M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -37.76 | 23.17 | -30.98 | -32.06 | -44.02 |
| ROA %i | -40.96 | -30.58 | -32.87 | -20.12 | 22.28 | -29.30 | -30.27 | -41.09 |
| ROIC %i | -- | -- | -- | -38.03 | 21.94 | -34.68 | -36.35 | -48.23 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -25.27 | -20.98 |
| EBIT margin %i | -- | -- | -- | -358.73 | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 25.85 | 39.67 | 14.82 | 25.25 | 21.09 | 17.07 | 13.53 | 10.25 |
| Quick ratioi | 25.55 | 39.09 | 14.68 | 24.73 | 20.77 | 16.60 | 13.02 | 10.01 |
| Debt / assetsi | -- | -- | -- | 0.00 | 0.92 | 0.74 | 0.35 | 0.60 |
| LT debt / equityi | -- | -- | -- | -- | 0.67 | 0.47 | 0.14 | 0.47 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 | 0.00 | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -36.57 | -36.01 | -40.18 | -44.02 | -48.16 | -50.30 |
| ROA %i | -34.74 | -34.42 | -38.13 | -41.09 | -44.99 | -46.30 |
| ROIC %i | -42.60 | -40.80 | -44.68 | -48.23 | -52.21 | -54.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.62 | 9.83 | 10.45 | 10.25 | 10.28 | 8.42 |
| Quick ratioi | 11.11 | 9.46 | 10.15 | 10.01 | 10.01 | 8.23 |
| Debt / assetsi | 0.32 | 0.29 | 0.25 | 0.60 | 0.59 | 0.57 |
| LT debt / equityi | 0.09 | 0.03 | -- | 0.47 | 0.45 | 0.44 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of developing immunology and oncology therapies100.00%
Region
United States100.00%
Quote time 2026-10-08 10:00:09 · For reference only, not investment advice and not tailored to your situation.